ATE447968T1 - Impfung mit immunisolierten und einen immunomodulator produzierenden zellen - Google Patents

Impfung mit immunisolierten und einen immunomodulator produzierenden zellen

Info

Publication number
ATE447968T1
ATE447968T1 AT03759977T AT03759977T ATE447968T1 AT E447968 T1 ATE447968 T1 AT E447968T1 AT 03759977 T AT03759977 T AT 03759977T AT 03759977 T AT03759977 T AT 03759977T AT E447968 T1 ATE447968 T1 AT E447968T1
Authority
AT
Austria
Prior art keywords
immunomodulator
vaccination
cells producing
relates
immune
Prior art date
Application number
AT03759977T
Other languages
English (en)
Inventor
Nicolas Mach
Original Assignee
Maxivax Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxivax Sa filed Critical Maxivax Sa
Application granted granted Critical
Publication of ATE447968T1 publication Critical patent/ATE447968T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03759977T 2002-06-17 2003-06-17 Impfung mit immunisolierten und einen immunomodulator produzierenden zellen ATE447968T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02013249A EP1374893A1 (de) 2002-06-17 2002-06-17 Impfung mit Immuno-isolierten Zellen die einen Immunomodulator Produzieren
PCT/EP2003/007140 WO2003105895A1 (en) 2002-06-17 2003-06-17 Vaccination with immuno-isolated cells producing an immunomodulator

Publications (1)

Publication Number Publication Date
ATE447968T1 true ATE447968T1 (de) 2009-11-15

Family

ID=29716769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03759977T ATE447968T1 (de) 2002-06-17 2003-06-17 Impfung mit immunisolierten und einen immunomodulator produzierenden zellen

Country Status (8)

Country Link
US (3) US20060024318A1 (de)
EP (3) EP1374893A1 (de)
AT (1) ATE447968T1 (de)
AU (1) AU2003246369A1 (de)
DE (1) DE60330004D1 (de)
DK (2) DK1513551T3 (de)
ES (2) ES2560105T3 (de)
WO (1) WO2003105895A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8180920B2 (en) * 2006-10-13 2012-05-15 Rgb Networks, Inc. System and method for processing content
WO2009125332A1 (en) * 2008-04-07 2009-10-15 Peter Bromley New and safe procedure for immunization against infectious diseases agents
US8551749B2 (en) * 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
DK3352783T3 (da) 2015-09-25 2021-11-15 Maxivax Sa Vaccine omfattende immun-isolerede celler som producerer en immunmodulator
WO2018044888A1 (en) * 2016-08-29 2018-03-08 Chen James C Tumor vaccination systems, devices, and methods
US20230272334A1 (en) * 2020-07-27 2023-08-31 Arizona Board Of Regents On Behalf Of Arizona State University Artificial placenta vaccine for organ transplantation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5955095A (en) * 1992-04-22 1999-09-21 Brown University Research Foundation Microporous macrocapsules
TNSN93075A1 (fr) * 1992-07-08 1994-03-17 Schering Corp Utilisation de gm-csf comme adjuvant pour vaccin
JPH09506866A (ja) * 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 医薬として活性のある物質の免疫療法のための放出制御
CA2267977A1 (en) 1996-10-16 1998-04-23 Matthew G. Ewend Cytokine enhanced immunotherapy for brain tumors
EP0983086B1 (de) 1997-02-05 2007-08-29 Jean-Claude Bystryn Ph-sensitive liposomen und andere typen immunomodulatoren enthaltender gekapselter impfstoffe sowie herstellungs- und anwendungsverfahren dafür
CA2318372C (en) * 1998-02-02 2008-08-19 Johns Hopkins University School Of Medicine A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
US7250291B1 (en) * 1998-08-07 2007-07-31 Dana-Farber Cancer Institute Tumor antigens and uses thereof
CN100425287C (zh) * 1999-02-09 2008-10-15 理化学研究所 肿瘤疫苗
US6916640B2 (en) * 2000-10-12 2005-07-12 Agency For Science, Technology And Research Multi-layer cell encapsulation for tissue engineering
FR2822707A1 (fr) * 2001-04-03 2002-10-04 Neurotech Association d'un antigene tumoral et d'un systeme de delivrance d'une cytokine ou d'une chemokine a des fins d'immunotherapie du cancer
WO2003094898A2 (en) * 2002-05-07 2003-11-20 Mcmaster University Microcapsules containing biomedical materials

Also Published As

Publication number Publication date
ES2335490T3 (es) 2010-03-29
EP1374893A1 (de) 2004-01-02
EP2147682B1 (de) 2015-11-11
EP2147682A3 (de) 2012-07-25
ES2560105T3 (es) 2016-02-17
EP2147682A2 (de) 2010-01-27
DK2147682T3 (en) 2016-02-01
US20080107686A1 (en) 2008-05-08
US20140341982A1 (en) 2014-11-20
DE60330004D1 (de) 2009-12-24
WO2003105895A1 (en) 2003-12-24
AU2003246369A1 (en) 2003-12-31
US20060024318A1 (en) 2006-02-02
US9814682B2 (en) 2017-11-14
DK1513551T3 (da) 2010-03-08
EP1513551A1 (de) 2005-03-16
EP1513551B1 (de) 2009-11-11

Similar Documents

Publication Publication Date Title
PL374782A1 (en) Animal protein free media for cultivation of cells
WO2004058157A3 (en) Yeast-based vaccines as immunotherapy
NO20015073L (no) Vaksiner
DE602004028468D1 (de) Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
DE69942176D1 (de) Choline-bindende proteine derivate aus pneumokoken als impfstoff
ATE460944T1 (de) Verfahren und zusammensetzungen zur herstellung und steuerung des effektorprofils von t-zellen durch gleichzeitiges beladen und aktivieren ausgewählter untergruppen von antigen- präsentierenden zellen
WO2005009463A3 (en) Antigen-presenting cell vaccines and methods of use thereof
WO2004084936A3 (en) Modified free-living microbes, vaccine compositions and methods of use thereof
DE69030172D1 (de) Impfstoffe gegen Krebs und Infektionskrankheiten
ATE421533T1 (de) Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
EA200301097A1 (ru) Иммунотерапевтические комбинации для лечения опухолей, которые сверхэкспрессируют ганглиозиды
EP2385060A3 (de) Verfahren und Zusammensetzungen zum Auslösen von multivalenten Immunreaktionen gegen auf Krebszellen und Tumor-Stroma exprimierte dominante und subdominante Epitope
DE60330004D1 (de) Impfung mit immunisolierten und einen immunomodulator produzierenden zellen
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
DE60331725D1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
DE60128070D1 (de) Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
NO20045587L (no) Liposom vaksineformulering for finne-fisk
ATE381942T1 (de) Mittel zur behandlung von infektionen mit leishmanien
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE526034T1 (de) Verbesserte inaktivierte fcv-vakzinen
ATE399794T1 (de) Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
ATE431156T1 (de) Verwendung des neutrophil-activating-protein von helicobacter pylori und/oder teile davon als adjuvant für die induktion einer t-helper type 1 (th1) immunantwort
WO2004000213A3 (en) Method for growing human organs, treating diseases, and increasing longevity
PL358081A1 (en) Inclusion bodies as antigenes in oral immunization of animals
ATE419003T1 (de) Mycobakterielle proteinantigene für krebstherapie und impfung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1513551

Country of ref document: EP